Jascayd US Data Backs Combination Therapy in 2 Pulmonary Fibrosis Types

4 articles · Updated · The Pharma Letter · May 22

New US subgroup results for Boehringer Ingelheim’s Jascayd, or nerandomilast, support using the drug in combination antifibrotic regimens for idiopathic and progressive pulmonary fibrosis.
The readout reinforces a broader treatment shift in fibrotic lung disease management, where combination therapy is gaining traction over single-agent approaches.
Boehringer’s data add momentum in 2 pulmonary fibrosis settings—IPF and PPF—strengthening the case for Jascayd’s role in evolving care strategies.

Can this new wave of combination drugs finally offer a path to reversing lung fibrosis, not just slowing it?

As new therapies emerge, how will doctors choose the right drug combination for individual lung fibrosis patients?

With expensive new drugs becoming standard, what is the real financial impact on lung disease patients and insurers?